Biomedical or Dental Material – Page 8

How the world’s biggest pharma and biotech companies paid their typical worker in 2023

1 year ago talkbio0Tagged 2023, Dosage Forms, Industry, Worker, world 's

Dosage Forms, Industry, world ‘s, Worker, 2023

Medical Devices Outshine Rx Drugs at Cannes Lions, Highlighting Shift in Customer Focus

1 year ago talkbio0Tagged Cannes, Customer, jury, Medical Devices, Panthera leo, President brand of dental material, RAX gene

Cannes Lions, Medical Devices, Rx Drugs, Customer Focus, Jury President

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

2 years ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

EMA Recommends Halt on Preterm Birth Medications Due to Safety Concerns

2 years ago talkbio0Tagged concerns, development aspects, European Medicines Agency, Fetus, Pregnancy, Safety, Suspensions

European Medicines Agency (EMA), safety committee, preterm birth drugs, suspension, safety concerns, pregnancy, fetal development.

Europe Temporarily Halts AstraZeneca’s Vaxzevria COVID-19 Vaccine on Company’s Request

2 years ago talkbio0Tagged AstraZeneca, authorization, concerns, COVID19 (disease), Europe, European Medicines Agency, Pharmacovigilance, Safety, Suspensions, Vaccines, Vaxzevria

AstraZeneca, Vaxzevria, COVID-19 vaccine, marketing authorization, suspension, Europe, European Medicines Agency (EMA), pharmacovigilance, safety concerns.

Pfizer Temporarily Suspends Dosing in Advanced Duchenne Muscular Dystrophy (DMD) Trial After Patient Fatality

2 years ago talkbio0Tagged Clinical Trials, concerns, DMD, dosing, Duchenne, Evaluation, halt, late-stage study, Muscular Dystrophy, Muscular Dystrophy, Duchenne, Pfizer, Safety, Suspensions, Transitory

Pfizer, Duchenne Muscular Dystrophy (DMD), clinical trial, dosing halt, patient death, late-stage study, temporary suspension, safety concerns, investigation.

Ono Pharmaceutical Strengthens Oncology Portfolio with Acquisition of Deciphera Pharmaceuticals for $2.4 Billion

2 years ago talkbio0Tagged Acquisition (action), cancer treatments, Clinical Development, Collaboration, Deciphera, Dosage Forms, expansion, Generalized, Market, Oncology Pipeline, strategic

Ono Pharmaceutical, Deciphera Pharmaceuticals, oncology pipeline, acquisition, $2.4 billion, cancer treatments, kinase inhibitors, strategic expansion, global market, clinical development, collaboration.

Endo’s Par Pharmaceutical Recalls Blood Pressure Medication Due to Potential Contamination

2 years ago talkbio0Tagged adulteration, blood pressure medication, Dosage Forms, Endometriosis, Expiration, function, hydrochlorothiazide, Mental Recall, mg/12.5, Tablet Dosage Form

Endo, Par Pharmaceutical, recall, blood pressure medication, contamination, quinapril HCl/ hydrochlorothiazide tablets, USP 20 mg/12.5 mg, lot number 0KG190092, expiration date 03/2022